Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Article Details
- CitationCopy to clipboard
DeAngelo DJ
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. doi: 10.1016/j.hoc.2009.07.008.
- PubMed ID
- 19825456 [ View in PubMed]
- Abstract
Nelarabine (506U78) is a soluble prodrug of 9- Darabinofuranosylguanine (ara-G), a deoxyguanosine derivative. Nelarabine has significant activity in patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL). Principal toxicity is grade 3 or 4 neutropenia and thrombocytopenia. Neurologic toxicity with Guillain-Barre syndrome, depressed level of consciousness, and peripheral neuropathy are concerning side effects. Nelarabine is well tolerated and has significant antitumor activity in T-ALL and T-LBL. Nelarabine was approved by the Food and Drug Administration for patients with T-ALL/LBL who failed at least two prior regimens. Nelarabine is being explored in children and will be explored in the near future in adults with newly diagnosed T-ALL.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Nelarabine DNA Nucleotide Humans YesIncorporation into and destabilizationDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Nelarabine Adenosine deaminase Protein Humans NoSubstrateDetails Nelarabine Deoxycytidine kinase Protein Humans NoSubstrateDetails Nelarabine Deoxyguanosine kinase, mitochondrial Protein Humans NoSubstrateDetails